Skip to main content
SpringerLink
Log in

Percutaneous dihydrotestosterone treatment

  • Chapter
Book cover Testosterone

Abstract

The aim of hormone replacement therapy is to obtain normal physiologic levels of sex steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahmed R, Boucher A, Manni A, Santen R, Bartholomew M, Demers L (1988) Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metabol 66: 546–551

    Article  CAS  Google Scholar 

  • Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet 25: 943–945

    Article  Google Scholar 

  • Behre HM, Nieschlag E (1992) Testosterone buciclate (20 Act-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long acting androgen ester. J Clin Endocrinol Metabol 75: 1204–1210

    Article  CAS  Google Scholar 

  • Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metabol 82: 2386–2390

    Article  CAS  Google Scholar 

  • Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metabol 74: 75–83

    Article  CAS  Google Scholar 

  • Bhasin S, Bremner WJ (1997) Emerging issues in androgen replacement therapy. J Clin Endocrinol Metabol 82: 3–8

    Article  CAS  Google Scholar 

  • Bulard J, Mowszowicz I, Schaison G (1987) Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. J Clin Endocrinol Metabol 64: 618–623

    Article  CAS  Google Scholar 

  • Cantril JA, Dewis P, Large DM, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol (Oxf), 21: 97–107

    Article  Google Scholar 

  • Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337: 91–95

    Article  PubMed  CAS  Google Scholar 

  • Delanoe D, Fougeyrollas B, Meyer L, Thonneau P (1984) Androgenization of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 4: 276–277

    Article  Google Scholar 

  • Delignieres B, Morville R (1980) Treatment of male hypogonadism by topical administration of androgens. Percutaneous absorption of steroids. P Mauvais-Jarvis, CFH/Vickers, J Wepierre (eds) Academic Press, pp 273–283

    Google Scholar 

  • Fiet J, Morville R, Chemama D, Vilette JM, Gourmel B, Brerault JL, Dreux C (1982) Percutaneous absorption of 5a dihydrotestosterone in man. I. Plasma androgen and gonadotropin levels in normal adult men after percutaneous administration of 5a didydrotestos- terone. Int J Androl 5: 586–594

    Article  PubMed  CAS  Google Scholar 

  • Findlay JC, Place VA, Snyder PJ (1989) Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 68: 369–373

    Article  PubMed  CAS  Google Scholar 

  • Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, Katznelson L, Walsh M, Guccione A, Cannan J, Heller H, Basgoz N, Klibanski A (1996) Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81: 4051–4058

    Article  PubMed  CAS  Google Scholar 

  • Jayle MF (1980) In memoriam. Percutaneous absorption of steroids. P Mauvais-Jarvis, CFH Vickers, J Wepierre (eds) Academic Press, 273–283

    Google Scholar 

  • Katz MD, Kligman I, Cai LQ, Zhu YS, Fratianni CM, Zervoudakis I, Rosenwaks Z, Imperato-McGinley J (1997) Paternity by intrauterine insemination with sperm from a man with 5a-reductase 2 deficiency. N Engl J Med 336: 994–997

    Article  PubMed  CAS  Google Scholar 

  • Korenman S, Viosca S, Garza D, Guralnik M, Place V, Campbell P, Davis S (1987) Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am J Med 83: 471–478

    Article  PubMed  CAS  Google Scholar 

  • Kuhn JM, Roca R, Laudat MH, Rieu M, Luton JP, Bricaire H (1983) Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol 19: 513–520

    Article  CAS  Google Scholar 

  • Kuhn JM, Rieu M, Laudat MH, Forest M, Pugeat M, Bricaire H, Luton JP (1984) Effects of 10 days administration of percutaneous dihydrotestosterone on the pituitary-testicular axis in normal men. J Clin Endocrinol Metab 58: 231–235

    Article  PubMed  CAS  Google Scholar 

  • Lindzey J, Wetsel WC, Stoker T, Cooper R, Couse JF, Korach KS (1997) Steroid regulation of hypothalamic GnRH and serum LH levels in male estrogen receptor knock out mice. The Endocrine Society 79th meeting. Minneapolis, MN: Abstract OR 16–3

    Google Scholar 

  • Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD (1992) Enhanced transdermal delivery of testosterone across the nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74: 623–628

    Article  PubMed  CAS  Google Scholar 

  • Moore N, Paux G, Noblet C, Andrejak M (1988) Spouse-related drug side-effects. Lancet 27: 468–469

    Article  Google Scholar 

  • Moore RJ, Gazak JM, Quebbeman JF, Wilson JD (1979) Concentration of dihydrotestosterone and 3a-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog. J Clin Invest 64: 1003–1009

    Article  PubMed  CAS  Google Scholar 

  • Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689–3698

    Article  PubMed  CAS  Google Scholar 

  • Schaison G, Renoir M, Lagoguey M, Mowszowicz I (1980) On the role of dihydrostestoster- one in regulating luteinizing hormone secretion in man. J Clin Endocrinol Metab 51: 1133–1137

    Article  PubMed  CAS  Google Scholar 

  • Sitruk-Ware R (1989) Transdermal delivery of steroids. Contraception 39: 1–191

    Article  PubMed  CAS  Google Scholar 

  • Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056–1061

    Article  PubMed  CAS  Google Scholar 

  • Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone en-anthate. J Clin Endocrinol Metab 51: 1335–1339

    Article  PubMed  CAS  Google Scholar 

  • Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37: 425–430

    PubMed  CAS  Google Scholar 

  • Spark R, Brewster SE, Libman H, Dezube BJ (1997) Dihydrotestosterone gel: a novel androgen for AIDS wasting syndrome. The Endocrine Society 79th meeting. Minneapolis, MN: Abstract PI–319

    Google Scholar 

  • Veldhuis JD, Rogol AD, Samojlik E, Ertel MH (1984) Role of endogenous opiates in the expression of negative feed back actions of androgens and estrogen on pulsatile properties of luteinizing-hormone secretion in man. J Clin Invest 74: 47–55

    Article  PubMed  CAS  Google Scholar 

  • Vermeiden A, Deslypere JP (1985) Long-term transdermal dihydrotestosterone therapy: effects on pituitary gonadal axis and plasma lipoproteins. Maturitas 7: 281–287

    Article  Google Scholar 

  • von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM (1997) Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein 11 and lipoprotein (a). J Clin Endocrinol Metabol 82: 3367–3372

    Article  Google Scholar 

Download references

Authors
  1. Gilbert Schaison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Béatrice Couzinet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Reproductive Medicine, University of Münster, Domagkstrasse 11, D-48129, Münster, Germany

    Eberhard Nieschlag  & Hermann M. Behre  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schaison, G., Couzinet, B. (1998). Percutaneous dihydrotestosterone treatment. In: Nieschlag, E., Behre, H.M. (eds) Testosterone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72185-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72185-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72187-8

  • Online ISBN: 978-3-642-72185-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation